oxycodone has been researched along with thiophenes in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 3 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Patel, TA; Rastogi, R; Swarm, RA | 1 |
| Bansal, M; Happich, M; Klein, R; Wielage, R; Wilson, K | 1 |
| Austin Zamarripa, C; Blough, BE; Edwards, SR; Freeman, KB; Qureshi, HN; Yi, JN | 1 |
| Bruno, V; Farcy, N; Karnik, V; Zamorano, C | 1 |
| Afzal, A; Blough, BE; Bossert, JM; Epstein, DH; Fredriksson, I; Hoots, JK; Kiyatkin, EA; Korah, H; Negus, SS; Perekopskiy, D; Shaham, Y; Thomas, S | 1 |
| Devi, LA; Fakira, AK; Kennedy, PJ | 1 |
3 review(s) available for oxycodone and thiophenes
| Article | Year |
|---|---|
Case scenario: opioid association with serotonin syndrome: implications to the practitioners.
Topics: Analgesics, Opioid; Antidepressive Agents, Tricyclic; Celecoxib; Chronic Pain; Cyclooxygenase 2 Inhibitors; Depressive Disorder; Desipramine; Drug Interactions; Duloxetine Hydrochloride; Fentanyl; Humans; Male; Methadone; Middle Aged; Oxycodone; Polypharmacy; Pyrazoles; Selective Serotonin Reuptake Inhibitors; Serotonin Syndrome; Sulfonamides; Thiophenes; Transdermal Patch | 2011 |
Cost-effectiveness of duloxetine in chronic low back pain: a Quebec societal perspective.
Topics: Age Factors; Aged; Amitriptyline; Analgesics; Cardiovascular Diseases; Celecoxib; Chronic Disease; Clinical Trials as Topic; Cost-Benefit Analysis; Duloxetine Hydrochloride; gamma-Aminobutyric Acid; Gastrointestinal Diseases; Humans; Hydromorphone; Low Back Pain; Markov Chains; Middle Aged; Models, Economic; Naproxen; Ontario; Osteoarthritis; Outcome Assessment, Health Care; Oxycodone; Pregabalin; Pyrazoles; Quality-Adjusted Life Years; Quebec; Sulfonamides; Thiophenes | 2013 |
Current Status of Pain Management in Parkinson's Disease.
Topics: Acetylcholine Release Inhibitors; Alanine; Analgesics; Antiparkinson Agents; Apomorphine; Benzylamines; Botulinum Toxins, Type A; Deep Brain Stimulation; Dopamine Agonists; Drug Combinations; Duloxetine Hydrochloride; Humans; Levodopa; Naloxone; Oxycodone; Pain; Pain Management; Pain Measurement; Pain Threshold; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes | 2020 |
3 other study(ies) available for oxycodone and thiophenes
| Article | Year |
|---|---|
The G-protein biased mu-opioid agonist, TRV130, produces reinforcing and antinociceptive effects that are comparable to oxycodone in rats.
Topics: Analgesics; Analgesics, Opioid; Animals; Conditioning, Operant; Dose-Response Relationship, Drug; GTP-Binding Proteins; Male; Morphine; Oxycodone; Pain; Rats; Rats, Sprague-Dawley; Receptors, Opioid, mu; Reinforcement, Psychology; Spiro Compounds; Thiophenes; Treatment Outcome | 2018 |
In a Rat Model of Opioid Maintenance, the G Protein-Biased Mu Opioid Receptor Agonist TRV130 Decreases Relapse to Oxycodone Seeking and Taking and Prevents Oxycodone-Induced Brain Hypoxia.
Topics: Analgesics, Opioid; Animals; Extinction, Psychological; Female; GTP-Binding Proteins; Humans; Hypoxia, Brain; Male; Oxycodone; Rats; Receptors, Opioid, mu; Recurrence; Self Administration; Spiro Compounds; Thiophenes | 2020 |
Novel Application for G Protein-Biased Mu Opioid Receptor Agonists in Opioid Relapse Prevention.
Topics: Analgesics, Opioid; Animals; GTP-Binding Proteins; Hypoxia, Brain; Oxycodone; Rats; Receptors, Opioid, mu; Recurrence; Secondary Prevention; Spiro Compounds; Thiophenes | 2020 |